Immunovia Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
18
- Stock Symbol
-
IMMNOV
Immunovia General Information
Description
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
Contact Information
Website
www.immunovia.comCorporate Office
- Medicon Village
- Scheelevägen 8
- 223 81 Lund
- Sweden
Corporate Office
- Medicon Village
- Scheelevägen 8
- 223 81 Lund
- Sweden
Immunovia Stock Performance
As of 16-Nov-2026, Immunovia’s current market cap is $3.16M with 1.01B shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.16M | 1.01B | 9.2M |
Immunovia Financials Summary
As of 30-Sep-2026, Immunovia has a trailing 12-month revenue of $208K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,094 | 15,948 | 3,630 | (14) |
| Revenue | 208 | 70 | 88 | 148 |
| EBITDA | (7,716) | (14,462) | (9,077) | (16,261) |
| Net Income | (8,109) | (14,852) | (7,237) | (29,112) |
| Total Assets | 3,211 | 9,586 | 2,995 | 9,874 |
| Total Debt | 293 | 93 | 62 | 1,027 |
Immunovia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immunovia Patents
Immunovia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4182692-A1 | Methods, arrays and uses thereof | Inactive | 16-Jul-2020 | ||
| GB-202010970-D0 | Methods, arrays and uses thereof | Inactive | 16-Jul-2020 | ||
| US-11320436-B2 | Methods, arrays and uses thereof | Inactive | 16-Jul-2020 | ||
| US-20220026431-A1 | Methods, arrays and uses thereof | Active | 16-Jul-2020 | ||
| US-20230296608-A1 | Methods, arrays and uses thereof | Inactive | 16-Jul-2020 | G01N33/57525 |
Immunovia Signals
Immunovia Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immunovia ESG
Risk Overview
Risk Rating
Updated December, 31, 2022
32.18 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Healthcare
Industry
of 581
Rank
Percentile
Medical Devices
Subindustry
of 199
Rank
Percentile
Immunovia FAQs
-
When was Immunovia founded?
Immunovia was founded in 2007.
-
Where is Immunovia headquartered?
Immunovia is headquartered in Lund, Sweden.
-
What is the size of Immunovia?
Immunovia has 18 total employees.
-
What industry is Immunovia in?
Immunovia’s primary industry is Diagnostic Equipment.
-
Is Immunovia a private or public company?
Immunovia is a Public company.
-
What is Immunovia’s stock symbol?
The ticker symbol for Immunovia is IMMNOV.
-
What is the current market cap of Immunovia?
The current market capitalization of Immunovia is $3.16M.
-
What is Immunovia’s current revenue?
The trailing twelve month revenue for Immunovia is $208K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process